Fredag 27 December | 11:03:29 Europe / Stockholm

Bifogade filer

Prenumeration

Kalender

Tid*
2025-05-22 N/A Årsstämma
2025-05-19 N/A Kvartalsrapport 2025-Q1
2025-02-20 N/A Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriBioteknik
Cinclus Pharma är ett svenskt läkemedelsbolag i klinisk fas. Bolaget är verksamt inom utveckling av molekyler för behandling av syrarelaterade sjukdomar. Bolagets ledande läkemedelskandidat linaprazan glurate utvecklas för behandling av svår gastroesofageal refluxsjukdom (GERD). Cinclus Pharma grundades år 2014 och har sitt huvudkontor i Stockholm.
2024-07-01 18:30:00

Carnegie Investment Bank AB (publ) (“Carnegie”), acting as stabilization manager, notifies that stabilization measures have been undertaken in the ordinary shares of Cinclus Pharma Holding AB (publ) (“Cinclus Pharma” or the “Company”) on Nasdaq Stockholm.

As announced on 20 June 2024 in connection with the offering of ordinary shares in the Company and the admission to trading of the Company’s ordinary shares on Nasdaq Stockholm, Carnegie is acting as stabilization manager and may effect transactions aimed at supporting the market price of the ordinary shares at levels above those which might otherwise prevail in the open market. Such stabilization transactions may be effected on Nasdaq Stockholm, in the over-the-counter market or otherwise, at any time during the period starting on the date of commencement of trading in the ordinary shares on Nasdaq Stockholm and ending no later than 30 calendar days thereafter.

Stabilization may terminate at any time without prior notice. In no event will transactions be effected at levels above the offering price of SEK 42. No later than by the end of the seventh trading day after stabilization transactions have been undertaken, Carnegie shall disclose that stabilization transactions have been undertaken. Within one week of the end of the stabilization period, Carnegie will make public the date at which stabilization started, the date at which stabilization last occurred and the price range within which stabilization was carried out, for each of the dates during which stabilization transactions were carried out.

The Company has granted an over-allotment option to Carnegie Investment Bank AB (publ), Bryan, Garnier & Co. Limited, Bryan Garnier Securities SAS and ABG Sundal Collier AB (the “Joint Bookrunners”), entailing that the Joint Bookrunners, no later than 30 days from the first day of trading in the Company’s ordinary shares on Nasdaq Stockholm, have the right to request that a maximum of 1,702,381 additional ordinary shares are issued by the Company, corresponding to a maximum of 10 percent of the total number of ordinary shares in the offering at a price corresponding to the offering price of SEK 42, in order to cover possible over-allotment within the framework of the offering.

Carnegie has, in its capacity as stabilization manager, notified that stabilization measures have been undertaken in accordance with article 5(4) in the Market Abuse Regulation 596/2014 and the Commission Delegated Regulation (EU) 2016/1052, on Nasdaq Stockholm as specified below.

The contact person at Carnegie is Anna Boqvist (phone: +46 (8) 5886 88 54).

Stabilization information
Issuer:Cinclus Pharma Holding AB (publ)
Securities:Ordinary shares, ISIN: SE0020388577
Offering size:18,726,191 ordinary shares (of which 1,702,381 refers to the over-allotment option)
Offering price:SEK 42
Ticker:CINPHA
Stabilization manager:Carnegie Investment Bank AB (publ)
Stabilization transactions
DateNumber of sharesHighest priceLowest priceVolume weighted
average price
CurrencyTrading venue
2024-06-20851,20340.000032.605037.4392SEKNasdaq Stockholm
2024-06-2481,17333.100032.115032.7209SEKNasdaq Stockholm
2024-06-2567,00533.100032.100032.6634SEKNasdaq Stockholm
2024-06-2620,00032.900030.500031.2225SEKNasdaq Stockholm
2024-06-2745,00031.000030.400030.6886SEKNasdaq Stockholm
2024-06-2840,00031.700031.000031.1908SEKNasdaq Stockholm
2024-07-0140,00031.800030.700031.4345SEKNasdaq Stockholm